PMID- 29716427
OWN - NLM
STAT- MEDLINE
DCOM- 20180705
LR  - 20190222
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 17
IP  - 6
DP  - 2018 Jun
TI  - The safety of dual bronchodilation on cardiovascular serious adverse events in 
      COPD.
PG  - 589-596
LID - 10.1080/14740338.2018.1472232 [doi]
AB  - INTRODUCTION: Long-acting beta(2)-adrenoceptor (beta(2)-AR) agonists (LABAs) plus 
      long-acting muscarinic antagonists (LAMAs) is the cornerstone for treating 
      chronic obstructive pulmonary disease (COPD). LABA/LAMA combinations elicit 
      clinical and functional synergistic interaction, and such an interaction should 
      permit to reduce the dose of each monocomponent in the drug mixture to minimize 
      the risk of adverse events (AEs). Overall, currently available LABA/LAMA 
      fixed-dose combinations (FDCs) combine the drugs at the same doses of 
      formulations designed for a single drug. Therefore, concerns regarding the 
      possible risk of cardiovascular AEs have been raised related to the use of 
      LABA/LAMA FDCs in COPD patients. AREAS COVERED: LABAs and LAMAs have a high 
      potential to induce cardiovascular AEs by stimulating the beta(2)-AR receptors and 
      inhibiting the muscarinic M(2) receptors expressed in the heart. This review will 
      explore the data published on the cardiovascular safety of dual bronchodilation 
      therapy in COPD patients. EXPERT OPINION: LABA/LAMA FDCs are characterized by an 
      acceptable cardiovascular safety profile, at least in the COPD population 
      enrolled in randomized clinical trials. Nevertheless, large real life studies 
      suggest that dual bronchodilation therapy may increase the risk of cardiovascular 
      AEs. Post-marketing surveillance and observational studies are needed to 
      adequately define the real cardiovascular safety profile of LABA/LAMA FDCs.
FAU - Rogliani, Paola
AU  - Rogliani P
AUID- ORCID: 0000-0001-7801-5040
AD  - a Department of Experimental Medicine and Surgery , University of Rome Tor 
      Vergata , Rome , Italy.
AD  - b Division of Respiratory Medicine , University Hospital Tor Vergata , Rome , 
      Italy.
FAU - Ora, Josuel
AU  - Ora J
AD  - b Division of Respiratory Medicine , University Hospital Tor Vergata , Rome , 
      Italy.
FAU - Matera, Maria Gabriella
AU  - Matera MG
AD  - c Department of Experimental Medicine , University of Campania Luigi Vanvitelli , 
      Naples , Italy.
FAU - Cazzola, Mario
AU  - Cazzola M
AUID- ORCID: 0000-0003-4895-9707
AD  - a Department of Experimental Medicine and Surgery , University of Rome Tor 
      Vergata , Rome , Italy.
FAU - Calzetta, Luigino
AU  - Calzetta L
AUID- ORCID: 0000-0003-0456-069X
AD  - a Department of Experimental Medicine and Surgery , University of Rome Tor 
      Vergata , Rome , Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180514
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - 0 (Muscarinic Antagonists)
SB  - IM
MH  - Adrenergic beta-2 Receptor Agonists/*administration & dosage/adverse effects
MH  - Bronchodilator Agents/administration & dosage/adverse effects/pharmacology
MH  - Cardiovascular Diseases/chemically induced
MH  - Delayed-Action Preparations
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Humans
MH  - Muscarinic Antagonists/*administration & dosage/adverse effects
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy
OTO - NOTNLM
OT  - COPD
OT  - LABA/LAMA FDCs
OT  - cardiovascular safety
EDAT- 2018/05/03 06:00
MHDA- 2018/07/06 06:00
CRDT- 2018/05/03 06:00
PHST- 2018/05/03 06:00 [pubmed]
PHST- 2018/07/06 06:00 [medline]
PHST- 2018/05/03 06:00 [entrez]
AID - 10.1080/14740338.2018.1472232 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2018 Jun;17(6):589-596. doi: 10.1080/14740338.2018.1472232. 
      Epub 2018 May 14.